Related Tags >> GlaxoSmithKline Type 1 Diabetes monoclonal antibody Biotech graveyard

Tolerx News

Most Popular Tolerx Story

Tolerx - 2008 Fierce 15

June 23, 2008 — 3:21pm ET | By John Carroll

Tolerx Based: Cambridge, MAFounded: 2000Website: www.tolerrx.com The Scoop: A rich partnership pact with GlaxoSmithKline last October kept Tolerx in the race Read more...

Tolerx Press Releases

Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
TOLERX AND GLAXOSMITHKLINE ANNOUNCE PHASE 3 DEFEND-1 STUDY OF OTELIXIZUMAB IN TYPE 1 DIABETES DID NOT MEET ITS PRIMARY ENDPOINT
Tolerx, Inc. and GlaxoSmithKline (GSK) Announce Phase 3 Defend-1 Study of Otelixizumab in Type 1 Diabetes Did Not Meet Its Prima
Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
Tolerx and the Cancer Research Institute Enter Collaboration to Accelerate Development of TRX518

Latest Headlines

Tolerx - The 2011 Biotech Graveyard
October 31, 2011
Exclusive: Tolerx cuts staff, auctioning assets after PhIII failure
October 7, 2011
GSK, Tolerx diabetes drug flunks PhIII
March 11, 2011
Tolerx faces moment of truth with pivotal trial
March 4, 2010
Tolerx - 2008 Fierce 15
June 23, 2008
Emerging Drug Developer: Tolerx
October 26, 2007
Emerging Drug Developer: Tolerx
October 25, 2007
GSK, Tolerx forge $760M development pact
October 23, 2007

Paid Research Reports

More Research Reports >>